Kidney outcomes in transthyretin amyloid cardiomyopathy
JAMA Cardiology
2024-11-17
(Press-News.org)
About The Study: In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.
Corresponding Author: To contact the corresponding author, Marianna Fontana, MD, PhD, email m.fontana@ucl.ac.uk.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4578)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4578?guestAccessKey=c1d676ce-acb0-403b-a519-25efb8f6e6c3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111724
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-11-17
About The Study: This randomized clinical trial found that partial cardiac denervation was an effective procedure to reduce the occurrence of postoperative atrial fibrillation (POAF) after isolated coronary artery bypass grafting (CABG) without additional postoperative complications. These results suggest that partial cardiac denervation may be a good option for cardiac surgeons to consider for preventing POAF after CABG.
Corresponding Authors: To contact the corresponding authors, email Wei Feng, MD, PhD (fengwei@fuwai.com) and Wei Zhao, MD, PhD (zhaowei_fw@163.com).
To access the embargoed study: Visit our For The Media website at ...
2024-11-17
About The Study: In the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF), finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, had similar tolerability in women and men.
Corresponding Author: To contact the corresponding author, John J. V. McMurray, MD, email john.mcmurray@glasgow.ac.uk.
To ...
2024-11-17
About The Study: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.
Corresponding Author: To contact the corresponding author, Scott D. Solomon, MD, email ssolomon@rics.bwh.harvard.edu.
To access the embargoed study: Visit our ...
2024-11-17
Skeletal size may be altered by gender-affirming hormone therapy only if puberty has also been suppressed during adolescence, according to research presented at the 62nd Annual European Society for Paediatric Endocrinology Meeting in Liverpool. The findings from this research, carried out by Amsterdam UMC, not only help researchers further understand the roles sex hormones play on the skeleton but may also improve counselling on gender-affirming treatment in transgender individuals.
Skeletons of men and women vary in size and proportion. For instance, men typically have broader shoulders while women have a wider pelvis. Gender-affirming hormones ...
2024-11-16
About The Study: Coronary heart disease polygenic risk scores that performed similarly at the population level demonstrated highly variable individual-level estimates of risk. Recognizing that coronary heart disease polygenic risk scores may generate incongruent individual-level risk estimates, effective clinical implementation will require refined statistical methods to quantify uncertainty and new strategies to communicate this uncertainty to patients and clinicians.
Corresponding Author: To contact the corresponding author, Scott M. Damrauer, MD, email Scott.Damrauer@pennmedicine.upenn.edu.
To access the embargoed study: Visit our For The Media website at this link ...
2024-11-16
About The Study: In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.
Corresponding Author: To contact the corresponding author, Benjamin D. Levine, MD, email benjaminlevine@texashealth.org.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4596)
Editor’s Note: Please see the article for additional information, including ...
2024-11-16
NEW ORLEANS (November 16, 2024) — Climate change is having a massive global impact on dengue transmission, accounting for 19% of the current dengue burden, with a potential to spark an additional 40%-60% spike by 2050 — and by as much as 150%-200% in some areas — according to a new study presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).
The findings from researchers at Stanford and Harvard Universities offer the most definitive evidence to date that climate change is ...
2024-11-16
A new study by heart researchers at Intermountain Health in Salt Lake City finds that patients with heart disease, specifically those with heart failure, are especially vulnerable to the impacts of air pollution and poor air quality and can take steps to protect themselves.
Results from the Intermountain Health study, presented on Saturday at the American Heart Association’s 2024 Scientific Sessions international conference in Chicago, found that two inflammatory markers — CCL27 (C-C motif chemokine ligand 27) ...
2024-11-16
SAN DIEGO, California (Nov. 16, 2024) — Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed that an algorithm fueled by artificial intelligence can accurately detect early-stage metabolic-associated steatotic liver disease (MASLD) by using electronic health records. The study was scheduled for presentation today at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases.
“A significant proportion of patients who meet criteria for MASLD go undiagnosed,” said Ariana Stuart MD, a resident at University of Washington Internal Medicine ...
2024-11-16
The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation Announce New Research Fellowship in Malaria Genomics in Honor of Professor Dominic Kwiatkowski
New Orleans, Louisiana, November 15, 2024 — The American Society of Tropical Medicine and Hygiene (ASTMH) is proud to announce the establishment of the annual Kwiatkowski Fellowship, a new research initiative in partnership with the Bill & Melinda Gates Foundation (BMGF). This fellowship honors the life and scientific contributions of the late Professor Dominic Kwiatkowski, a pioneer in the field of malaria genomics.
The ...
LAST 30 PRESS RELEASES:
[Press-News.org] Kidney outcomes in transthyretin amyloid cardiomyopathy
JAMA Cardiology
